当前位置： SCI文献检索 > ANTIVIRAL THERAPY期刊下所有文献 > On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy.

On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy.

Abstract：

BACKGROUND:Serum HBV RNA is detectable during nucleoside/nucleotide analogue therapy as a result of unaffected RNA replicative intermediates or interrupted reverse transcription. We studied the predictive value of serum HBV RNA for initial virological response during nucleoside analogue therapy. METHODS:Serum HBV RNA was quantified before and at 12 and 24 weeks of lamivudine or entecavir therapy. Serum HBV DNA was measured every 4-12 weeks during treatment to define initial virological response. RESULTS:Serum HBV RNA was detectable in 21 of 52 (40%) consecutive patients with a mean of 5.2 log copies/ml (male/female 35/17, mean age of 60 years with a range of 31-82, 44% HBeAg-positive, and 26 with lamivudine and 26 with entecavir) before treatment. Serum HBV RNA level at week 12 in patients with an interval from detectable to undetectable serum HBV DNA level <16 weeks was significantly lower than those with an interval ≥16 weeks (3.8 ±3.8 versus 6.6 ±3.5 log copies/ml, P=0.013). After adjustment for serum HBV DNA level at week 12, serum quantatitive HBsAg level at week 12 and pretreatment ALT level, low serum HBV RNA level at week 12 predicted a shorter interval to undetectable serum HBV DNA level (adjusted hazard ratio =0.908, 95% CI 0.829, 0.993, P=0.035). CONCLUSIONS:Low serum HBV RNA level at week 12 of nucleoside analogue therapy independently predicts initial virological response in treated chronic hepatitis B patients. Serum HBV RNA levels may thus be useful for optimizing treatment of chronic hepatitis B.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Huang YW,Takahashi S,Tsuge M,Chen CL,Wang TC,Abe H,Hu JT,Chen DS,Yang SS,Chayama K,Kao JH

doi

10.3851/IMP2777

subject

Has Abstract

pub_date

2015-01-01 00:00:00

pages

369-75

issue

4

eissn

1359-6535

issn

2040-2058

journal_volume

20

pub_type

杂志文章

相关文献

ANTIVIRAL THERAPY文献大全
  • Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV.

    abstract：BACKGROUND:Monocytes transmigrating to the brain play a central role in HIV neuropathology. We hypothesized that the continued existence of neurocognitive impairment (NCI) despite potent antiretroviral (ARV) therapy is mediated by the inability of such therapy to control this monocyte/macrophage reservoir. METHODS:Cro...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2411

    authors： Shikuma CM,Nakamoto B,Shiramizu B,Liang CY,DeGruttola V,Bennett K,Paul R,Kallianpur K,Chow D,Gavegnano C,Hurwitz SJ,Schinazi RF,Valcour VG

    更新日期：2012-01-01 00:00:00

  • The influence of HIV infection and antiretroviral therapy on the mitochondrial membrane potential of peripheral mononuclear cells.

    abstract：OBJECTIVES:Clinical disorders occurring in HIV-infected patients on antiretroviral therapy (ART) have been linked to mitochondrial dysfunction, for example, lactic acidosis and lipodystrophy. Mitochondrial membrane potential (delta psi m) is the most direct measure of the state of energization of the mitochondria. We a...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章

    doi：

    authors： Sternfeld T,Schmid M,Tischleder A,Mudra S,Schlamp A,Kost BP,Gruber R,Youle M,Bogner JR,Goebel FD

    更新日期：2007-01-01 00:00:00

  • Effect of individual cognitive behaviour intervention on adherence to antiretroviral therapy: prospective randomized trial.

    abstract：OBJECTIVE:A high level of adherence to antiretroviral therapy is required for complete suppression of HIV replication, immunological and clinical effectiveness. We investigated whether cognitive behaviour therapy can improve medication adherence. DESIGN:Prospective randomized 1-year trial. SETTING:Collaboration of HI...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：

    authors： Weber R,Christen L,Christen S,Tschopp S,Znoj H,Schneider C,Schmitt J,Opravil M,Günthard HF,Ledergerber B,Swiss HIV Cohort Study.

    更新日期：2004-02-01 00:00:00

  • Predicting antiretroviral drug resistance from the latest or the cumulative genotype.

    abstract：BACKGROUND:This study evaluates the added benefit when estimating antiretroviral drug resistance of combining all available resistance test results in a cumulative genotype relative to using the latest genotype alone. METHODS:The prevalence of resistance and genotypic sensitivity scores (GSS) predicted by the latest a...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1753

    authors： Garcia F,Alvarez M,Fox Z,Garcia-Diaz A,Guillot V,Johnson M,Chueca N,Phillips A,Hernández-Quero J,Geretti AM

    更新日期：2011-01-01 00:00:00

  • Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.

    abstract：BACKGROUND:The emergence of human monkeypox and the potential use of recombinant variola and monkeypox viruses as biological terrorist agents have necessitated the development of therapeutic and prophylactic therapies. The primary, or index, cases of smallpox and/or human monkeypox will likely be identified by a charac...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Parker S,Schriewer J,Oberle C,Robertson A,Lanier R,Painter G,Buller RM

    更新日期：2008-01-01 00:00:00

  • The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.

    abstract：BACKGROUND:The nucleotide analogue, tenofovir, has been shown to lower plasma atazanavir levels in pharmacokinetic trials, an interaction that may be partly reversed by the addition of ritonavir, whereas plasma tenofovir levels are themselves raised when the drug is combined with lopinavir/ritonavir. OBJECTIVE:To inve...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章

    doi：

    authors： Kruse G,Esser S,Stocker H,Breske A,Koerber A,Kopperman M,Wiehler H,Ross B,Möcklinghoff C,Hill A,Becker M,Kurowski M

    更新日期：2005-01-01 00:00:00

  • Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-

    abstract：BACKGROUND:Once-daily dosing of abacavir and lamivudine has been approved for adults, but paediatric data are insufficient. We conducted a pharmacokinetic study of once-daily and twice-daily abacavir and lamivudine in children aged 3-<36 months. METHODS:Children with stable HIV type-1 (HIV-1) RNA levels after 12 weeks...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.3851/IMP1532

    authors： Paediatric European Network for Treatment of AIDS (PENTA).

    更新日期：2010-01-01 00:00:00

  • Risk of cardiovascular disease associated with HCV and HBV coinfection among antiretroviral-treated HIV-infected individuals.

    abstract：BACKGROUND:The increased risk for cardiovascular disease (CVD) in HIV is well established. Despite high prevalence of viral hepatitis coinfection with HIV, there are few studies on the risk of CVD amongst antiretroviral therapy (ART)-treated coinfected patients. METHODS:Ontario HIV Treatment Network Cohort Study parti...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2724

    authors： Gillis J,Smieja M,Cescon A,Rourke SB,Burchell AN,Cooper C,Raboud JM,OHTN Cohort Study Group.

    更新日期：2014-01-01 00:00:00

  • Impact of tenofovir dose adjustment on both estimated glomerular filtration rate and tenofovir trough concentration.

    abstract：BACKGROUND:Tenofovir disoproxil fumarate (TDF)-based regimen is a treatment option for HIV-infected patients. TDF dose adjustment is recommended in patients with impaired renal function. We assessed the impact of TDF dose adjustment on renal function and tenofovir trough concentration. METHODS:Fourteen HIV patients fo...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3137

    authors： Bregigeon S,Solas C,Faucher O,Obry-Roguet V,Tamalet C,Poizot-Martin I

    更新日期：2017-01-01 00:00:00

  • HIV type-1 transmission dynamics in recent seroconverters: relationship with transmission of drug resistance and viral diversity.

    abstract：BACKGROUND:HIV type-1 (HIV-1) has been shown to be frequently transmitted by acutely infected patients. We investigated the relationship between the dynamics of HIV-1 transmission within recently infected patients, the HIV-1 variability and the transmission of antiretroviral drug resistance. METHODS:We included patien...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Recordon-Pinson P,Anies G,Bruyand M,Neau D,Morlat P,Pellegrin JL,Groppi A,Thiébaut R,Dabis F,Fleury H,Masquelier B,ANRS CO3 Aquitaine Cohort.

    更新日期：2009-01-01 00:00:00

  • Association between systemic inflammation and obstructive sleep apnea in men with or at risk for HIV infection.

    abstract：BACKGROUND:We sought to determine whether markers of systemic inflammation are associated with the presence of moderate/severe obstructive sleep apnea (OSA) and whether this association differs based on HIV and HIV treatment status. METHODS:HIV-uninfected men (HIV-; n=60), HIV-infected men receiving HAART (HIV+/HAART;...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：10.3851/IMP2745

    authors： Brigham EP,Patil SP,Jacobson LP,Margolick JB,Godfrey R,Johnson J,Johnson-Hill LM,Reynolds S,Schwartz AR,Smith PL,Brown TT

    更新日期：2014-01-01 00:00:00

  • Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4

    abstract：OBJECTIVE:To assess the effect of interleukin (IL)-2 combined with highly active antiretroviral therapy (HAART) on HIV-1 pro-viral DNA quantification in HIV-1-infected patients with CD4<200/mm3. PATIENTS AND METHODS:Seventy patients with CD4<200 cells/mm3 and CV<1000 copies/ml were enrolled in a 6-month randomized con...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：

    authors： Delaugerre C,Gourlain K,Tubiana R,Carcelain G,Marcelin AG,Chouquet C,Mouroux M,Duvivier C,Autran B,Costagliola D,Katlama C,Calvez V

    更新日期：2003-06-01 00:00:00

  • Maternal antiretroviral prophylaxis and breastfeeding.

    abstract：:The prevention of mother-to-child transmission of HIV-1 during breastfeeding is a major concern in resource-poor settings where alternatives to breast milk may be unaffordable, unsafe and limited by social stigma. The use of triple-drug antiretroviral regimens initiated during pregnancy and continued throughout breast...

    journal_title：Antiviral therapy

    pub_type： 评论,杂志文章

    doi：10.3851/IMP2314

    authors： Marzolini C,Gray GE

    更新日期：2012-01-01 00:00:00

  • Patients' preferences regarding the timing of highly active antiretroviral therapy initiation for chronic asymptomatic HIV-1 infection.

    abstract：OBJECTIVE:In patients with a chronic asymptomatic HIV-1 infection and >200 CD4+ T-cells/microl, the optimal timing of highly active antiretroviral therapy (HAART) initiation is unclear. It involves a trade-off between a potentially reduced risk of mortality, when started earlier in the course of infection, and an earli...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Locadia M,van Grieken RA,Prins JM,de Vries HJ,Sprangers MA,Nieuwkerk PT

    更新日期：2006-01-01 00:00:00

  • Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy.

    abstract：OBJECTIVE:To estimate the treatment and health care costs of HIV infection or AIDS in France during the era of highly active antiretroviral therapy (HAART). DESIGN:We used a clinical database of HIV-infected patients to calculate the resource use and cost of care for different stages of HIV infection. Costs were incor...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Yazdanpanah Y,Goldie SJ,Losina E,Weinstein MC,Lebrun T,Paltiel AD,Seage GR 3rd,Leblanc G,Ajana F,Kimmel AD,Zhang H,Salamon R,Mouton Y,Freedberg KA

    更新日期：2002-12-01 00:00:00

  • Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.

    abstract：BACKGROUND:Mutations in the genome of HIV conferring drug resistance are a major reason for the failure of antiretroviral therapy, but they often compromise viral fitness. Protease (PR) cleavage site (CS) mutations could compensate for impaired replication capacity of drug-resistant viruses. PATIENTS AND METHODS:We an...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Verheyen J,Litau E,Sing T,Däumer M,Balduin M,Oette M,Fätkenheuer G,Rockstroh JK,Schuldenzucker U,Hoffmann D,Pfister H,Kaiser R

    更新日期：2006-01-01 00:00:00

  • Factors associated with HIV RNA levels in pregnant women on non-suppressive highly active antiretroviral therapy at conception.

    abstract：BACKGROUND:Little is known about pregnancy patterns and levels of HIV RNA in HIV-infected women conceiving on highly active antiretroviral therapy (HAART) with non-suppressed viral load (VL), nor about their therapeutic management. METHODS:Linear mixed models were fitted to study changes in VL and potential associated...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：10.3851/IMP1489

    authors： European Collaborative Study.

    更新日期：2010-01-01 00:00:00

  • HCV's days are numbered: next-generation direct-acting antivirals and host-targeting agents.

    abstract：:Chronic hepatitis C affects approximately 170 million people worldwide and is one of the leading causes of liver-related morbidity and mortality. Until 2011, the only therapeutic option was combination therapy of pegylated interferon and ribavirin, with efficacy rates around 50% and plenty of side effects. In the past...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2425

    authors： Calle Serrano B,Manns MP

    更新日期：2012-01-01 00:00:00

  • Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy.

    abstract：BACKGROUND:Longitudinal assessment of liver fibrosis with transient elastometry (TE) in patients with chronic viral hepatitis is becoming routine clinical practice in many clinics, as this procedure is non-invasive, easy to perform and relatively inexpensive, allowing early detection of cirrhosis. Herein, we examine th...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1630

    authors： Tuma P,Medrano J,Resino S,Vispo E,Madejón A,Sánchez-Piedra C,Rivas P,Labarga P,Martín-Carbonero L,Barreiro P,Soriano V

    更新日期：2010-01-01 00:00:00

  • Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels.

    abstract：BACKGROUND:Quantification of HBsAg in serum may be of clinical importance in predicting HBsAg seroconversion and complete response to treatment. METHODS:Serum HBsAg was quantified by ADVIA Centaur in 63 patients with HBeAg-negative chronic hepatitis B (CHBe-). A total of 42 had received interferon-alpha2b (IFN-alpha2b...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Manesis EK,Hadziyannis ES,Angelopoulou OP,Hadziyannis SJ

    更新日期：2007-01-01 00:00:00

  • Factors associated with non-adherence to HBV antiviral therapy.

    abstract：BACKGROUND:HBV antiviral therapy has the potential to reduce the burden of HBV-related liver disease by suppressing HBV DNA replication to undetectable levels, reducing the progression of liver fibrosis and reducing the risk of hepatocellular carcinoma (HCC) development. Treatment outcomes and long-term benefits requir...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：10.3851/IMP3219

    authors： Sheppard-Law S,Zablotska-Manos I,Kermeen M,Holdaway S,Lee A,George J,Zekry A,Maher L

    更新日期：2018-01-01 00:00:00

  • Glycated haemoglobin in diabetic women with and without HIV infection: data from the Women's Interagency HIV Study.

    abstract：BACKGROUND:Limited data suggest that glycated haemoglobin (haemoglobin A1c; A1C) values might not reflect glycaemic control accurately in HIV-infected individuals with diabetes. METHODS:We evaluated repeated measures of paired fasting glucose and A1C values in 315 HIV-infected and 109 HIV-uninfected diabetic participa...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1557

    authors： Glesby MJ,Hoover DR,Shi Q,Danoff A,Howard A,Tien P,Merenstein D,Cohen M,Golub E,Dehovitz J,Nowicki M,Anastos K

    更新日期：2010-01-01 00:00:00

  • Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus.

    abstract：BACKGROUND:Human cytomegalovirus (HCMV) infections remain a major problem in immunocompromised patients. Three antiviral agents, ganciclovir (GCV), foscarnet (FOS) and cidofovir (CDV), are currently approved for the treatment of HCMV infections. They all target the viral DNA polymerase and are associated with significa...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3028

    authors： Drouot E,Piret J,Boivin G

    更新日期：2016-01-01 00:00:00

  • HIV RNA viral load and CD4+ T-cell counts in HIV-infected pregnant women with and without treatment discontinuation in early pregnancy.

    abstract：BACKGROUND:In pregnant women taking antiretroviral treatment at conception treatment may be transiently stopped for safety concerns. Limited data are available on the consequences of such discontinuations. METHODS:We used data from a national study to compare different treatment pathways during pregnancy. Overall, 321...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Tamburrini E,Ravizza M,Floridia M,Tibaldi C,Alberico S,Anzidei G,Maccabruni A,Meloni A,Antoni AD,Mori F,Dalzero S,Conservan V,Pinnetti C,Ferrazzi E,Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy.

    更新日期：2008-01-01 00:00:00

  • Darunavir minimum plasma concentration and ritonavir-boosted darunavir monotherapy outcome in HIV-infected patients.

    abstract：BACKGROUND:This study aimed to evaluate whether low darunavir (DRV) minimum plasma concentration (Cmin) values contribute to virological outcomes during DRV/ritonavir monotherapy (mtDRV/rtv). METHODS:This was a prospective observational single-arm 96-week efficacy study in virologically suppressed subjects on triple t...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2722

    authors： Gutierrez-Valencia A,Torres-Cornejo A,BenMarzouk-Hidalgo OJ,Ruiz-Valderas R,Lluch A,Viciana P,López-Cortés LF

    更新日期：2014-01-01 00:00:00

  • Viral hepatitis and HIV: update and management.

    abstract：:HCV-related liver disease is an important contributor to morbidity and mortality in the HIV-infected population. Successful treatment of HIV-HCV-coinfected patients is followed by favourable clinical outcomes. While the combination of pegylated interferon and ribavirin remains the mainstay in the treatment of non-1 HC...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2601

    authors： Núñez M,Mendes-Correa MC

    更新日期：2013-01-01 00:00:00

  • Assessing bias introduced in estimated glomerular filtration rate (eGFR) by the inhibition of creatinine tubular secretion from common antiretrovirals.

    abstract：BACKGROUND:Researchers must often rely on creatinine measurements to assess kidney function because direct glomerular filtration rates (GFR) and cystatin-c are rarely measured in routine clinical settings. However, HIV treatments often include dolutegravir, raltegravir, rilpivirine or cobicistat, which inhibit the prox...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3373

    authors： Brunet L,Wyatt C,Hsu R,Mounzer K,Fusco J,Fusco G

    更新日期：2020-11-19 00:00:00

  • Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay.

    abstract：BACKGROUND:Patients infected with hepatitis C virus (HCV) who respond to treatment with interferon-alpha plus ribavirin exhibit biphasic or triphasic viral load decreases. While the rapid first phase is indicative of the effectiveness of therapy in blocking viral production (epsilon), the slope of the final phase (lamb...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Dahari H,Shudo E,Cotler SJ,Layden TJ,Perelson AS

    更新日期：2009-01-01 00:00:00

  • The impact of ribavirin plasma concentration on the efficacy of the interferon-sparing regimen, sofosbuvir and ribavirin.

    abstract：BACKGROUND:Ribavirin augments sustained virological response when administered with pegylated interferon for the treatment of chronic HCV infection. The impact of ribavirin plasma concentration on outcome in individuals receiving interferon-free regimens has not been evaluated. METHODS:Stored plasma samples were retri...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2984

    authors： Martinello M,Schteinman A,Alavi M,Williams K,Dore GJ,Day R,Matthews GV

    更新日期：2016-01-01 00:00:00

  • Protective murine and human monoclonal antibodies against eczema vaccinatum.

    abstract：BACKGROUND:Eczema vaccinatum is the most common severe pathology associated with smallpox vaccination (vaccinia virus), occurring at high rates among individuals with a previous history of atopic dermatitis (atopic eczema). METHODS:Monoclonal antibodies capable of neutralizing vaccinia virus, anti-H3 and anti-B5, were...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1717

    authors： Tomimori Y,Kawakami Y,McCausland MM,Ando T,Koriazova L,Kato S,Kawakami T,Crotty S

    更新日期：2011-01-01 00:00:00